Document is current
Any future updates will be listed below
-
Authors
Enders, Christian https://orcid.org/0000-0003-3922-3765
Duncker, Tobias https://orcid.org/0000-0001-9824-422X
Schürks, Markus https://orcid.org/0000-0002-0477-8288
Scholz, Paula https://orcid.org/0000-0002-1730-0566
Dörner, Julia https://orcid.org/0000-0001-7815-7196
Müller, Christian https://orcid.org/0000-0002-3722-7685
Wachtlin, Joachim https://orcid.org/0000-0001-5355-5729
Lommatzsch, Albrecht https://orcid.org/0000-0001-9640-4103
-
Funding
Funding for this research was provided by:
Bayer Vital
- License Information
-
More Information
Article History
Received: 5 September 2022
Revised: 23 November 2022
Accepted: 10 December 2022
First Online: 23 December 2022
Declarations
:
: This survey was classified as market research, which is exempt for an ethics approval. This survey does not include any access to identifiable private information, personal characteristics, or disease-related information of the participants.
: Informed consent was obtained from all participants included in the study.
: CE received consulting fees from Novartis Pharma GmbH, Nuremberg, Germany and Bayer Vital GmbH, Leverkusen, Germany. CE received financial support from Carl Zeiss Meditec AG, Jena, Germany. MS, PS, JD, and CM are employees of Bayer Vital GmbH. JW received consulting and speaking fees within the last 5 years from Alcon, Bayer, Novartis, Roche, Allergan. AL received consulting and speaker fees from Bayer, Novartis, Roche, Allergan, Inceptua and Zeiss.TD certifies that he has no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
